Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.
NaviFUS Corp. is dedicated to advancing non-invasive treatments for complex brain disorders, a challenging area in medical innovation. By using ultrasound technology for both diagnosis and therapy, ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...
FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.
This new review article highlights the crucial role of GATA6, a transcription factor, in pancreatic ductal adenocarcinoma (PDA). The article explores ...
PUBG's very own Brenden Green - better known as PlayerUnknown - wants his new simulation game, made at his new studio, to ...
ABS-CBN on MSN21h
Unlocking the future of cancer care with Next-Generation Sequencing: Why the Philippines must keep upIn the Philippines, access to comprehensive genomic profiling (CGP), circulating tumor DNA (ctDNA), and cell-free DNA (cfDNA) ...
Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback